[Edaily Starin Gim Ga Yeong Reporter] Amid heated debate among viewers over actor Jung Joon-won’s behavior on MBC’s “What Do You Do When You’re Bored?”, Haha has come to Jung Joon-won’s defense.
On the 3rd, Haha commented on a social media post about Jung Joon-won, explaining, “I was there on set, and he was so lovable, cute, and funny,” adding, “His reactions were meant to liven things up.” Previously, Jung Joon-won appeared on MBC’s *What Do You Do When You’re Bored?* and appeared extremely nervous. The *What Do You Do When You’re Bored?* team made various requests of Jung Joon-won, and he even closed his eyes tightly due to his nerves. Jung Joon-won tried to compose himself by saying, “I can do this,” but Yoo Jae-suk wrapped things up by saying, “Time’s up.” Seeing how nervous Jung Joon-won was, Yoo Jae-suk even remarked, “I think viewers will be wondering, ‘When on earth is he going to speak?’” After the scene aired, some netizens pointed out that Jung Joon-won’s attitude went beyond mere “nervousness” and bordered on indifference. As the controversy spread, Haha stepped in to clarify the situation. Haha said, “‘What Do You Do When You Play?’ is a really tough show, especially for a first-time variety show appearance. Since he’s not a professional variety show performer, please be kind and enjoy the show,” adding, “Please have a happy day today. Let’s give the actor a round of applause. Please cheer him on.” Meanwhile, Jung Jun-won is currently starring in MBC’s new Friday-Saturday drama, “Married Woman Killer.”
“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
#The BORN Korea announced on the 13th that it posted a consolidated operating loss of 3.7 billion won in the third quarter of this year. This represents an improvement in the loss compared to the same…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…